NBIX
HealthcareNeurocrine Biosciences, Inc. · Biotechnology · $16B
What is Neurocrine Biosciences, Inc.?
Neurocrine Biosciences is a San Diego-based biopharmaceutical company focused on neurological, endocrine, and psychiatric disorders. Founded in 1996, it has built a commercial portfolio anchored by treatments for tardive dyskinesia, Parkinson's disease, and women's health conditions.
Neurocrine generates revenue primarily through commercializing specialty pharmaceuticals targeting underserved neurological and endocrine conditions. Its lead product, INGREZZA, treats tardive dyskinesia — a movement disorder with limited treatment options. Beyond INGREZZA, the company markets therapies for Parkinson's disease, endometriosis pain, and uterine fibroid-related bleeding. A pipeline of clinical-stage candidates in epilepsy, major depressive disorder, and schizophrenia represents the next potential wave of growth, supported by licensing and collaboration agreements with multiple biotech and pharmaceutical partners.
Neurocrine Biosciences was founded in 1996 and is headquartered in San Diego, California.
- INGREZZA — VMAT2 inhibitor for tardive dyskinesia
- ONGENTYS — adjunct therapy for Parkinson's disease
- ORILISSA — treatment for moderate-to-severe endometriosis pain
- ORIAHNN — oral option for uterine fibroid-related heavy menstrual bleeding
- Pipeline candidates in epilepsy, depression, and schizophrenia
Is NBIX a Good Stock to Buy?
UQS Score rates NBIX as Good overall, reflecting a balanced profile with meaningful strengths and one notable area of concern.
The Growth and Risk pillars both register as Strong, suggesting Neurocrine is expanding its business at an above-average pace while maintaining a risk profile that compares favorably within the healthcare sector. The Quality pillar also lands at Good, indicating the underlying business fundamentals are sound relative to peers.
The Moat pillar is rated Weak, which signals that Neurocrine's competitive advantages — while present — may not be as durable or wide as those of larger, more diversified pharmaceutical companies.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NBIX pay dividends?
No — Neurocrine Biosciences, Inc. does not currently pay a dividend.
Neurocrine Biosciences does not currently pay a dividend. This is common among commercial-stage biopharmaceutical companies that prioritize reinvesting cash into pipeline development, clinical trials, and potential business development opportunities. Investors in NBIX are generally seeking capital appreciation tied to pipeline progress rather than income from distributions.
When does NBIX report earnings?
Neurocrine Biosciences reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Quarterly results for NBIX tend to center on INGREZZA prescription trends, pipeline milestone updates, and operating expense management. The company's Growth pillar rating of Strong suggests its revenue trajectory has been moving in a positive direction relative to sector peers.
For the most recent quarter's results and upcoming reporting dates, visit Neurocrine Biosciences' investor relations page directly.
NBIX Price History
+69.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Neurocrine Biosciences, Inc.?
Based on Neurocrine Biosciences, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
NBIX Long-term Outlook
Neurocrine's Strong Growth pillar points to a business with meaningful forward momentum, driven by continued commercial execution of its lead asset and expanding pipeline optionality. The Strong Risk pillar suggests the company is navigating sector-specific uncertainties — such as patent exposure and clinical trial outcomes — with relative discipline. However, the Weak Moat rating is a reminder that competitive pressures or generic entry could weigh on long-term pricing power.
Growth drivers
- Continued INGREZZA prescription volume growth in tardive dyskinesia
- Pipeline advancement in epilepsy, depression, and schizophrenia indications
- Collaboration and licensing agreements providing non-dilutive milestone revenue
Key risks
- Weak moat rating signals limited long-term pricing power versus larger pharma peers
- Pipeline clinical failures could reset growth expectations materially
- Concentration risk from heavy reliance on a single lead commercial asset
NBIX vs Peers
Neurocrine operates in a competitive specialty pharma landscape; the peers below represent companies tracked alongside NBIX on UQS Score.
Regencell focuses on traditional Chinese medicine-based approaches to neurodevelopmental conditions, a fundamentally different R&D model than Neurocrine's small-molecule drug platform.
Elanco operates in animal health rather than human therapeutics, making it a structurally distinct business despite sharing a broad healthcare classification.
Dr. Reddy's is a global generics and branded pharmaceutical company with a broad geographic footprint, contrasting with Neurocrine's focused US specialty commercialization strategy.
Frequently Asked Questions
What does Neurocrine Biosciences do?
Neurocrine Biosciences discovers, develops, and commercializes pharmaceuticals targeting neurological, endocrine, and psychiatric disorders. Its marketed products address tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, while its pipeline targets epilepsy, major depressive disorder, and schizophrenia.
Does NBIX pay dividends?
No, Neurocrine Biosciences does not currently pay a dividend. The company reinvests its resources into clinical development and commercial operations, which is typical for specialty biopharmaceutical companies at this stage of growth.
When does NBIX report earnings?
Neurocrine Biosciences follows a standard quarterly earnings cadence for US-listed companies. For confirmed dates and the most recent results, check the investor relations section of the company's official website.
Is NBIX a good stock to buy?
UQS Score rates NBIX as Good overall. The Growth and Risk pillars are both Strong, while the Moat pillar is Weak. Whether NBIX fits your portfolio depends on your own investment criteria — the full pillar breakdown is available to UQS Pro members.
Is NBIX overvalued?
The UQS Valuation pillar for NBIX is rated Good, suggesting the stock is not trading at an extreme premium relative to its fundamentals when compared to sector peers. The complete valuation metrics are available in the Pro analysis.
How does NBIX compare to its competitors?
Neurocrine's focused specialty pharma model — anchored by INGREZZA — differentiates it from generics-oriented peers like Dr. Reddy's and sector-adjacent companies like Elanco. Its Strong Growth rating suggests it is outpacing several peers on a revenue trajectory basis.
What is NBIX's market cap bracket?
Neurocrine Biosciences is classified as a large-cap company, placing it among the more established players in the specialty biopharmaceutical space — larger than most clinical-stage biotechs but smaller than mega-cap diversified pharmaceutical companies.
Who founded Neurocrine Biosciences?
Neurocrine Biosciences was founded in 1996. For detailed founding history and leadership background, the company's official about page and public filings provide comprehensive information.
Is NBIX a long-term quality investment?
From a quality indicator standpoint, NBIX's Strong Risk and Growth pillars alongside a Good Quality rating suggest a reasonably durable business. The Weak Moat rating is worth monitoring over a longer horizon, as competitive durability matters for sustained long-term performance.
What is the main competitive advantage of Neurocrine Biosciences?
Neurocrine's primary commercial advantage stems from INGREZZA's established position in the tardive dyskinesia market, a condition with historically limited treatment options. Its pipeline breadth across multiple CNS and psychiatric indications also provides optionality, though the UQS Moat pillar rates its overall competitive position as Weak.
What sector does NBIX belong to?
NBIX operates in the Healthcare sector, specifically within specialty biopharmaceuticals. The company focuses on neurological, endocrine, and psychiatric conditions — a niche that requires significant R&D investment and regulatory expertise.
Is NBIX a growth stock or value stock?
Based on UQS pillar labels, NBIX leans toward the growth side — its Growth pillar is rated Strong while its Valuation pillar is rated Good rather than Attractive. This profile is more consistent with a growth-oriented holding than a deep-value opportunity.
Unlock Full NBIX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare NBIX against sector peers side by side
- ✓Track pipeline risk and moat durability indicators
- ✓Get the full analyst-grade quality and valuation view
Pro Analysis
NBIX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | 15.0 | 0.0 | 38.0 | 0.0 | 36.9 | 0.0 | -51.2 |
| Aug 5, 2026 | 66.2 | 79.7 | 38.0 | 89.8 | 60.6 | 64.6 | 0.0 |
| Aug 3, 2026 | 66.2 | 79.7 | 38.0 | 89.8 | 60.6 | 64.8 | -0.6 |
| Aug 2, 2026 | 66.8 | 79.7 | 38.0 | 89.8 | 64.0 | 65.4 | -0.9 |
| Aug 1, 2026 | 67.7 | 80.2 | 38.0 | 89.8 | 73.2 | 61.1 | +0.1 |
| Jul 29, 2026 | 67.6 | 80.3 | 38.0 | 89.8 | 73.2 | 60.8 | -0.2 |
| Jul 25, 2026 | 67.8 | 80.7 | 38.0 | 89.8 | 73.2 | 61.3 | -0.1 |
| Jul 24, 2026 | 67.9 | 80.8 | 38.0 | 89.8 | 73.2 | 61.6 | 0.0 |
| Jul 23, 2026 | 67.9 | 80.9 | 38.0 | 89.8 | 73.2 | 61.6 | +0.3 |
| Jul 22, 2026 | 67.6 | 80.5 | 38.0 | 89.8 | 73.2 | 60.4 | -0.4 |
NBIX — Pillar Breakdown
Quality
— 0.0/100 (25%)Neurocrine Biosciences, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Neurocrine Biosciences, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)Neurocrine Biosciences, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Neurocrine Biosciences, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 38/100 (25%)Neurocrine Biosciences, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NBIX.
Score Composition
Financial Data
More Stock Analysis
How is the NBIX UQS Score Calculated?
The UQS (Unified Quality Score) for Neurocrine Biosciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Neurocrine Biosciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Neurocrine Biosciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.